A New Building Block for Nanostructures - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A New Building Block for Nanostructures

NMR, crystallography, and native MS reveal a modular protein–foldamer interface for assembling defined molecular architectures

  • August 27, 2026

  • 3 min

Share

Clinical Scorecard: A New Building Block for Nanostructures

At a Glance

CategoryDetail
ConditionNanostructure Engineering
Key MechanismsModular protein–foldamer pair with defined binding interface for hybrid nanostructures
Target PopulationResearchers in materials science and nanotechnology
Care SettingLaboratory research

Key Highlights

  • Development of a protein–foldamer pair for nanostructure assembly
  • C10 protein variant shows high affinity binding to synthetic foldamer
  • Use of various spectroscopy techniques to analyze binding and structure
  • Ability to modify foldamer length and geometry for diverse protein arrangements
  • Potential applications in constructing porous three-dimensional materials

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Clinical Best Practices

          • Utilize modular protein–foldamer pairs for precise nanostructure assembly
          • Employ spectroscopy techniques for structural analysis of protein complexes
          • Explore modifications in foldamer design to enhance assembly properties

          Related Resources & Content

            Original Source(s)

            A New Building Block for Nanostructures

            • August 27, 2026

            Related Content

            Productive Dentist Academy Opens 2027 Planning Session to Dental Practices

            October virtual program will address financial goals, staffing, marketing, operations and investments.

            Fatal Police Pursuits and Neighborhood Opportunity—Interpreting and Acting on a Concentrated Harm

            Roswell Park-Led Study Shows Promise for New Targeted Combination in People With Relapsed AML

            New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational treatment approach using the targeted therapy ziftomenib for patients with a difficult-to-treat form of acute myeloid leukemia (AML).

            • by

            • August 26, 2026

            • 3 min